Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. Atomoxetine is a selective norepinephrine re-uptake inhibitor. It appears to work by blocking or slowing the reabsorption of norepinephrine...
Strattera (atomoxetine hcl) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults. Strattera should be used as part of a total treatment program for ADHD that may include counseling or other therapies...
Researchers have identified a new brain signaling pathway that alleviates depression when blocked; the discovery could open the door to new treatments.
Although the average lifespan of humans has steadily increased over the last century, new research shows there may be a ceiling on maximum age.
New research finds even with charity or cash incentives, regularly wearing activity trackers may increase exercise levels, but not enough to boost health.